Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

IDEAYA Biosciences (IDYA) Gains from Sales and Divestitures (2019 - 2021)

IDEAYA Biosciences (IDYA) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $7312.0 as the latest value for Q4 2021.

Quarterly Gains from Sales and Divestitures changed N/A to $7312.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $7312.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $7312.0 for FY2021, N/A changed from the prior year.
Gains from Sales and Divestitures hit $7312.0 in Q4 2021 for IDEAYA Biosciences, roughly flat from $7312.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $7312.0 in Q1 2021 to a low of $4099.0 in Q2 2019.